ArticleBMC cancer2025
Clinical characteristics and survival outcomes of well-responders following definite comprehensive treatment in locally advanced rectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Adequacy and Baseline Risk Modify the Association Between Adjuvant Chemotherapy and Survival After Pathological Complete Response in Rectal Cancer.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients with a tumor regression grade of 0 or 1 (CAP), are classified as well-responders after neoadjuvant chemoradiotherapy (NCRT). Although well-responders are expected to have superior prognosis, occurrences of recurrence and metastasis still exist.
methodsClinical data of patients from January 2017 to 2022 were analyzed. INCLUSION CRITERIA: adenocarcinoma, cT3-4N0 or cTanyN+, receiving NCRT and surgery, CAP 0 ~ 1. The primary endpoint was three-year disease-free survival (3y-DFS). According to occurrence of DFS events, patients were divided into DFS (470, 91.8%) and non-DFS group (42, 8.2%). Cox regression analysis was applied to identify risk factors affecting prognosis of well-responders.
resultsA total of 512 well-responders were included, with mean age of 59.1 ± 10.6 years. Compared to DFS group, patients in non-DFS group had advanced mrT4 stage (33.3% vs. 18.1%, P = 0.017), higher positive rates of mesorectal fascia (52.4% vs. 35.1%, P = 0.026) and extramural vascular invasion (59.5% vs. 36.6%, P = 0.003), advanced ypT4 stage (56.2% vs. 23.8%, P < 0.001), ypN+ (23.8% vs. 9.4%, P = 0.014), and tumor deposits (14.3% vs. 3.6%, P = 0.005). The follow-up was end up to May 2024, with a duration of 36 (18 to 53) months. The tumor recurrence and metastasis rates were 0.8% (4) and 7.0% (36). The estimated 3y-DFS and overall survival in well-responders were 90.1% and 97.4%. Cox analysis identified ypT3 ~ 4 stage as independent risk factor resulting inferior DFS.
conclusionWell-responders are expected to have superior prognosis. Special attention should be given to patients with advanced stages or those exhibiting positive mesorectal fascia or extramural vascular invasion, or adverse pathological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.